This article only represents the author's own views.
After 18 months without a chief executive, innovative drug maker I-Mab (IMAB.US) could finally be getting just the medicine it needs with a newly named CEO. And if Raj Kannan’s past record is any guide, a sale of the company may be in the cards.
I-Mab announced the new appointment of Kannan last Thursday, settling on an industry veteran with more than 30 years of experience at global companies. He joined I-Mab from U.S.-based Aerie Pharmaceuticals, a clinical-stage pharmaceutical company like I-Mab.
您已閱讀9%（555字），剩餘91%（5930字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。